|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM108858502 |
003 |
DE-627 |
005 |
20231222150109.0 |
007 |
tu |
008 |
231222s2000 xx ||||| 00| ||eng c |
028 |
5 |
2 |
|a pubmed24n0363.xml
|
035 |
|
|
|a (DE-627)NLM108858502
|
035 |
|
|
|a (NLM)10964538
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Xu, L Y
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Combined nasal administration of encephalitogenic myelin basic protein peptide 68-86 and IL-10 suppressed incipient experimental allergic encephalomyelitis in Lewis rats
|
264 |
|
1 |
|c 2000
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
500 |
|
|
|a Date Completed 22.09.2000
|
500 |
|
|
|a Date Revised 30.11.2018
|
500 |
|
|
|a published: Print
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a Copyright 2000 Academic Press.
|
520 |
|
|
|a Mucosal administration of low doses of myelin basic protein (MBP) peptide 68-86 (MBP 68-86) or anti-inflammatory cytokine IL-10 effectively prevented experimental allergic encephalomyelitis (EAE), but failed to suppress the disease if given after 7 days postimmunization (p.i.), i.e., after T cell priming had occurred. We anticipated that combined administration of autoantigen and IL-10 can treat incipient EAE. Lewis rats with EAE actively induced with MBP 68-86 and complete Freund's adjuvant received 120 microg MBP 68-86 + 200 ng IL-10 per rat per day from day 7 p.i. and for 5 consecutive days. These rats showed later onset, lower clinical scores, less body weight loss, and shorter duration of EAE than rats receiving MBP 68-86 or IL-10 only or PBS. EAE amelioration was associated with decreased infiltration of ED1(+) macrophages and CD4(+) T cells within the central nervous system and with decreased proliferative responses of lymph node cells, indicating that combined administration of MBP 68-86 and IL-10 induced immune hyporesponsiveness. IFN-gamma secretion as well as IFN-gamma, TNF-alpha, IL-4, and IL-10 mRNA expression by lymph node MNC was down-regulated in the treated rats. Immune hyporesponsiveness, rather than immune deviation or regulatory mechanisms, seems to be responsible for the protection of EAE after autoantigen + IL-10 administration by the nasal route
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
650 |
|
7 |
|a Antigens
|2 NLM
|
650 |
|
7 |
|a Cytokines
|2 NLM
|
650 |
|
7 |
|a Myelin Basic Protein
|2 NLM
|
650 |
|
7 |
|a Peptide Fragments
|2 NLM
|
650 |
|
7 |
|a RNA, Messenger
|2 NLM
|
650 |
|
7 |
|a myelin basic protein 68-86
|2 NLM
|
650 |
|
7 |
|a Interleukin-10
|2 NLM
|
650 |
|
7 |
|a 130068-27-8
|2 NLM
|
650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
650 |
|
7 |
|a 82115-62-6
|2 NLM
|
700 |
1 |
|
|a Yang, J S
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Huang, Y M
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Levi, M
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Link, H
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Xiao, B G
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 96(2000), 3 vom: 01. Sept., Seite 205-11
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
773 |
1 |
8 |
|g volume:96
|g year:2000
|g number:3
|g day:01
|g month:09
|g pages:205-11
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_11
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 96
|j 2000
|e 3
|b 01
|c 09
|h 205-11
|